1035 related articles for article (PubMed ID: 12917955)
1. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
2. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
Shelley MD; Wilt TJ; Court J; Coles B; Kynaston H; Mason MD
BJU Int; 2004 Mar; 93(4):485-90. PubMed ID: 15008714
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
[TBL] [Abstract][Full Text] [Related]
4. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M
Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738
[TBL] [Abstract][Full Text] [Related]
6. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
[TBL] [Abstract][Full Text] [Related]
7. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
Shelley MD; Kynaston H; Court J; Wilt TJ; Coles B; Burgon K; Mason MD
BJU Int; 2001 Aug; 88(3):209-16. PubMed ID: 11488731
[TBL] [Abstract][Full Text] [Related]
9. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
10. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
11. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
12. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
14. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
15. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
16. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
17. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
[TBL] [Abstract][Full Text] [Related]
18. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
19. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
20. WITHDRAWN: Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T I bladder cancer.
Shelley M; Court JB; Kynaston HG; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2015 Nov; (11):CD003231. PubMed ID: 26544085
[No Abstract] [Full Text] [Related]
[Next] [New Search]